← SynDRA
TERAZOSIN
SynDRA canonical compound SYN0001152 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | ADRA1A |
|---|
| Mechanism of action | Adrenergic receptor antagonist |
|---|
| Indication | benign prostatic hyperplasia (BPH) | hypertension |
|---|
| Disease area | cardiology | urology |
|---|
All known targets
- ADRA1D
- ADRA1A
- ADRA1B
- ADRA2A
- ADRA2B
- ADRA2C
- Adra1a
- Adra1b
- Adra1d
- Adra2b
- HTR2A
- KCNH2
Mechanisms of action (all sources)
- Adrenergic receptor antagonist
- ADRA1A ANTAGONIST
- Adrenergic receptor alpha-1 antagonist
- ADRA1D ANTAGONIST
- ADRA1B ANTAGONIST
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- OPRK1
- OPRM1
- LMNA
- MAOA
- MAPK1
- MAPK14
- MAPK3
- MBD4
- MC3R
- ABCC2
- KDM4E
- MC4R
- MC5R
- MLNR
- MMP1
- MMP9
- MPG
- MUTYH
- LCK
- KDM4A
- NEIL2
- HRH2
- GMNN
- GPR119
- GPR35
- HDAC6
- HMGCR
- HPGD
- HRH1
- HRH3
- IDH1
- HSD17B10
- HTR1A
- HTR2B
- HTR2C
- HTR3A
- HTR6
- HTT
- NEIL1
- NFE2L2
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- ACES
- CP2C9
- G3P
- HDAC9
- LYAG
- NSD2
- SC5A7
Drug classes
- Adrenergic alpha-Antagonists
- alpha-Adrenergic Blocker
- Adrenergic Agents
- Adrenergic alpha-1 Receptor Antagonists
- Adrenergic Antagonists
- Neurotransmitter Agents
- Urological Agents
ATC classes
- G04C · DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
Cross-references
Synonyms
- HYTRIN
- TERAZOSIN HYDROCHLORIDE
- TEZRULY
- Tezruly
- terazosin hydrochloride
- terazosin hydrochloride anhydrous
- terazosine
- terazosin hydrochloride hydrate
- terazosin HCl
- Terazosine
- Terazosina
- Terazosabb
- Blavin
- Flumarc
- Fosfomic
- Hytracin
- Hytrin
- Terazosinum
- Vasomet
- Trazosin HCl
- A-45975
- Abbott 45975
- Hytrin (TN)
- Terazosabb (TN)
- Terazosin (INN)
- Terazosin [INN:BAN]
- Terazosina [INN-Spanish]
- Terazosine [INN-French]
- Terazosinum [INN-Latin]
- 8L5014XET7
- terazocin
- Hytrinex
- Vicard
- CHEBI:9445
- RefChem:57178
- DTXCID003639
- G04CA03
- terazosin, monohydrochloride, dihydrate
Reported adverse events
- Asthenia
- Atrial fibrillation
- Hypertension
- Amblyopia
- Depression
- Dizziness
- Headache
- Hypotension
- Nausea
- Nervousness
- Palpitations
- Rhinitis
Look up TERAZOSIN in the interactive SynDRA portal →